MV 2101

Drug Profile

MV 2101

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Miravant Medical Technologies
  • Class Cardiovascular therapies
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Vascular graft occlusion

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Vascular-graft-occlusion in USA
  • 12 Jul 2004 Miravant and Guidant have entered into an agreement to co-develop PhotoPoint technology
  • 23 Dec 2003 MV 2101 has received orphan drug status in the USA for the prevention of graft occlusion in patients undergoing dialysis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top